Many hypothesis suggest that inflammation plays an important role in schizophrenia. Galectins can regulate inflammatory response in central nervous system. The relation between galectins and neuropsyhchiatric diseases and schizophrenia is unclear. The present study compared levels of Gal-1 and Gal-3 of patients with schizophrenia to that of first-degree relatives without the disease and healthy controls in order to evaluate any possible association. Sixty-two patients with schizophrenia, fifty-five unaffected siblings and fifty-eight age- and sex-matched healthy controls enrolled. Serum Gal-1, Gal-3 and CRP levels were measured. PANNS and CGI-S were used to evaluate the severity of disease. There was a statistically significant difference in serum Gal-1 levels among the patient, sibling, and control groups. There were no statistically significant correlations between serum CRP and serum Gal-1 or Gal-3 levels. Gal-1 values were significantly higher in the unaffected siblings compared to both the patient group and the healthy control group. Gal-3 levels were elevated in the sibling group relative to the patient group. In the literature, the relationship between galectins and schizophrenia is very limited and appears to be a new field of study. Future studies are needed to evaluate the protective roles of galectins.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Bernardes ES, Silva NM, Ruas LP, Mineo JR, Loyola AM, Hsu DK, et al. Toxoplasma gondii infection reveals a novel regulatory role for galectin-3 in the interface of innate and adaptive immunity. Am J Pathol. 2006;168:1910–20.
Brown AS. The environment and susceptibility to schizophrenia. Prog Neurobiol. 2011;93:23–58.
Chen HL, Liao F, Lin TN, Liu FT. Galectins and neuroinflammation. Springer, New York: In glycobiology of the nervous system; 2014. p. 517–42.
Colnot C, Ripoche MA, Milon G, Montagutelli X, Crocker P, Poirier F. Maintenance of granulocyte numbers during acute peritonitis is defective in galectin-3-null mutant mice. Immunology. 1998;94:290–6.
Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res. 2007;93:261–5.
Dong H, Wang Z-H, Zhang N, Liu SD, Zhao JJ, Liu SY (2017) Serum Galectin-3 level, not Galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke. Oncotarget8:109752.
Egnaczyk GF, Pomonis JD, Schmidt JA, Rogers SD, Peters C, Ghilardi JR, et al. Proteomic analysis of the reactive phenotype of astrocytes following endothelin-1 exposure. Proteomics. 2003;3:689–98.
Elola M, Wolfenstein-Todel C, Troncoso M, Vasta G, Rabinovich G. Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci. 2007;64:1679–700.
Hanson DR, Gottesman II. Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med Genet. 2005;6:7.
He J, Baum LG. Galectin interactions with extracellular matrix and effects on cellular function. Methods Enzymol. 2006;417:247–56.
Hsu DK, Yang RY, Pan Z, Yu L, Salomon DR, Fung-Leung W-P, et al. Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol. 2000;156:1073–83.
Hsuchou H, Kastin AJ, Mishra PK, Pan W (2012) C-reactive protein increases BBB permeability: implications for obesity and neuroinflammation. Cell Physiol Biochem30:1109–1119.
Inoshita M, Numata S, Tajima A, Kinoshita M, Umehara H, Nakataki M, et al. A significant causal association between C-reactive protein levels and schizophrenia. Sci Rep. 2016;6:26105.
Joseph J, Depp C, Martin AS, Daly RE, Glorioso DK, Palmer BW, et al. Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups. Schizophr Res. 2015;168:456–60.
Kajitani K, Yanagimoto K, Nakabeppu Y. Serum galectin-3, but not galectin-1, levels are elevated in schizophrenia: implications for the role of inflammation. Psychopharmacology. 2017;234:2919–27.
Kaltner H, Seyrek K, Heck A, Sinowatz F, Gabius HJ. Galectin-1 and galectin-3 in fetal development of bovine respiratory and digestive tracts. Cell Tissue Res. 2002;307:35–46.
Kirkpatrick B, Miller BJ. Inflammation and schizophrenia. Schizophr Bull. 2013;39:1174–9.
Kuhlmann CR, Librizzi L, Closhen D, Pflanzner T, Lessmann V, Pietrzik CU, et al. Mechanisms of C-reactive protein-induced blood-brain barrier disruption. Stroke. 2009;40:1458.
Lai C-Y, Scarr E, Udawela M, Everall I, Chen WJ, Dean B (2016) Biomarkers in schizophrenia: a focus on blood based diagnostics and theranostics. World J Psychiatry6:102.
Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer. 2005;5:29.
Liu W, Hsu DK, Chen HY, Yang RY, Carraway KL 3rd, Isseroff RR, et al. Galectin-3 regulates intracellular trafficking of EGFR through Alix and promotes keratinocyte migration. J Invest Dermatol. 2012;132:2828–37.
Maes M, Delange J, Ranjan R, Meltzer HY, Desnyder R, Cooremans W, et al. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res. 1997;66:1–11.
McGraw J, Gaudet A, Oschipok L, Kadoya T, Horie H, Steeves J, Tetzlaff W, Ramer M (2005) Regulation of neuronal and glial galectin-1 expression by peripheral and central axotomy of rat primary afferent neurons. Exp Neurol195:103–114.
Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry70:663–671.
Miller BJ, Culpepper N, Rapaport MH (2013) C-reactive protein levels in schizophrenia: a review and meta-analysis. Clin Schizophr Relat Psychoses7:223–230.
Müller N, Riedel M, Gruber R, Ackenheil M, Schwarz MJ. The immune system and schizophrenia: an integrative view. Ann N Y Acad Sci. 2000;917:456–67.
Nonaka M, Fukuda M. Galectin-1 for neuroprotection? Immunity. 2012;37:187–9.
Rabinovich GA, Baum LG, Tinari N, Paganelli R, Natoli C, Liu FT, et al. Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol. 2002;23:313–20.
Rawson ES, Freedson PS, Osganian SK, Matthews CE, Reed G, Ockene IS (2003) Body mass index, but not physical activity, is associated with C-reactive protein. Med Sci Sports Exerc35:1160–1166.
Richard MD, Bram NC (2012) Schizophrenia and the immune system: pathophysiology, prevention, and treatment. Am J Health Syst Pharm69:757–766.
Shin T (2013) The pleiotropic effects of galectin-3 in neuroinflammation: a review. Acta Histochemica1 15:407-411.
Singh B, Chaudhuri TK. Role of C-reactive protein in schizophrenia: an overview. Psychiatry Res. 2014;216:277–85.
Sirko S, Irmler M, Gascón S, Bek S, Schneider S, Dimou L, et al. Astrocyte reactivity after brain injury: the role of galectins 1 and 3. Glia. 2015;63:2340–61.
Starossom SC, Mascanfroni ID, Imitola J, Cao L, Raddassi K, Hernandez SF, et al. Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity. 2012;37:249–63.
Tandon R, Keshavan MS, Nasrallah HA (2008) Schizophrenia,“just the facts” what we know in 2008. 2. Epidemiology and etiology. Schizophr Res 102:1–18, Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology.
Timpson NJ, Nordestgaard BG, Harbord RM, Zacho J, Frayling TM, Tybjærg-Hansen A, et al. C-reactive protein levels and body mass index: elucidating direction of causation through reciprocal Mendelian randomization. Int J Obes. 2011;35:300.
Venkatraman A, Hardas S, Patel N, Singh Bajaj N, Arora G, Arora P. Galectin-3: an emerging biomarker in stroke and cerebrovascular diseases. Eur J Neurol. 2018;25:238–46.
Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131–5.
Wada M, Ono S, Kadoya T, Kawanami T, Kurita K, Kato T. Decreased galectin-1 immunoreactivity of the skin in amyotrophic lateral sclerosis. J Neurol Sci. 2003;208:67–70.
Wang X, Zhang S, Lin F, Chu W, Yue S. Elevated galectin-3 levels in the serum of patients with Alzheimer's disease. Am J Alzheimers Dis Other Dement. 2015;30:729–32.
Wang Z, Li P, Chi D, Wu T, Mei Z, Cui G. Association between C-reactive protein and risk of schizophrenia: an updated meta-analysis. Oncotarget. 2017;8:75445.
Windgassen EB, Funtowicz L, Lunsford TN, Harris LA, Mulvagh SL. C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians. Postgrad Medicine. 2011;123:114–9.
Yang Y, Wan C, Li H, Zhu H, La Y, Xi Z, et al. Altered levels of acute phase proteins in the plasma of patients with schizophrenia. Anal Chem. 2006;78:3571–6.
Yip PK, Carrillo-Jimenez A, King P, Vilalta A, Nomura K, Chau CC, et al. Galectin-3 released in response to traumatic brain injury acts as an alarmin orchestrating brain immune response and promoting neurodegeneration. Sci Rep. 2017;7:41689.
Yüksel RN, Ertek IE, Dikmen AU, Göka E. High neutrophil-lymphocyte ratio in schizophrenia independent of infectious and metabolic parameters. Nord Journal Psychiat. 2018;72:336–40.
Conflict of Interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
Declaration of Interest
No potential conflict of interest was reported by the authors.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The original version of this article was revised: The spelling of the family name of the fifth author was corrected.
About this article
Cite this article
Yüksel, R.N., Göverti, D., Kahve, A.C. et al. Galectin-1 and Galectin-3 Levels in Patients with Schizophrenia and their Unaffected Siblings. Psychiatr Q 91, 715–725 (2020). https://doi.org/10.1007/s11126-020-09731-8
- Galectin 1
- Galectin 3